Investment
Features
FeesSafety
Academy
More
Pluang+

Compare C3.ai Inc (AI) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance

Charles River Laboratories Intl. IncTrade

Price performance (Past 24H)

Key statistics

C3.ai Inc vs Charles River Laboratories Intl. Inc — how do they compare? C3.ai Inc trades at $10.25 (market cap $1.65B), while Charles River Laboratories Intl. Inc trades at $286.87 (market cap $13.46B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 8.2× C3.ai Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, C3.ai Inc nearer its low. Which is the better fit depends on your goals.

AICRL
Market Cap
$1.65B$13.46B
Sector
TechnologyHealth
52-Week High
$19.66$282.00
52-Week Low
$7.76$145.57
Enterprise Value
$1.08B$16.30B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

C3.ai Inc

C3.ai (AI) trades at $10.25, down 1.44% on the day, with mixed technical signals showing bullish moving averages but overbought RSI readings. The company maintains strong revenue growth, reaching $389 million in 2025, but continues to report significant losses with a -74.21% net margin. Recent positive developments include being named a Leader in AI Platforms by Forrester Research.

While technical indicators suggest short-term bullish momentum, fundamental challenges persist with consistent negative profitability. The stock faces execution risk in achieving profitability despite growing enterprise AI adoption. Analyst consensus remains cautious with only 21% buy ratings and a $10.20 price target slightly below current levels.

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.

While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.

Returns comparison

Trailing returns across standard periods

About C3.ai Inc

C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type

Read more on AI

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL